MRNA - Better Buy: Moderna vs Axsome
Moderna (NASDAQ: MRNA) and Axsome Therapeutics (NASDAQ: AXSM) are early in their revenue stories. Moderna launched its first product -- the COVID-19 vaccine -- in 2020. Axsome started selling its first two products -- a sleep disorder drug and an antidepressant -- this year.
Both stocks have delivered great returns to early investors. In 2020, Moderna shares soared more than 400%. This year, Axsome has gained about 100%. These exciting biotech companies each have late-stage candidates in the pipeline and offer promising futures. But which one represents the best buy today? Let's find out.
Moderna's share price performance disappointed this year. The stock is heading for a 25% loss. That's because investors have worried about Moderna's earnings prospects once the pandemic is over.
For further details see:
Better Buy: Moderna vs Axsome